Author Contributions Conceived and designed the experiments: MS DA SN. Performed the experiments: MS DA NC EF LS. Analyzed the data: MS DA NC LS SN. References 1. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. (2005) A microRNA polycistron as a potential human oncogene. Nature 435: 828–833. 2. Knoepfler PS (2007) Myc goes global: new tricks for an old oncogene. Cancer Res 67: 5061–5063. 3. Martinato F, Cesaroni M, Amati B, Guccione E (2008) Analysis of Myc-induced histone modifications on target chromatin. PLoS One 3: e3650. 4. Meyer N, Penn LZ (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976–990. 5. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, et al. (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297: 102–104. 6. Dang CV, McGuire M, Buckmire M, Lee WM (1989) Involvement of the ‘leucine zipper’ region in the oligomerization and transforming activity of human c-myc protein. Nature 337: 664–666. 7. Mukherjee B, Morgenbesser SD, DePinho RA (1992) Myc family oncoproteins function through a common pathway to transform normal cells in culture: cross- interference by Max and trans-acting dominant mutants. Genes Dev 6: 1480–1492. 8. Wanzel M, Herold S, Eilers M (2003) Transcriptional repression by Myc. Trends Cell Biol 13: 146–150. 9. Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, et al. (1998) Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 17: 2463–2472. 10. Soucek L, Jucker R, Panacchia L, Ricordy R, Tato F, et al. (2002) Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res 62: 3507–3510. 11. Soucek L, Nasi S, Evan GI (2004) Omomyc expression in skin prevents Myc- induced papillomatosis. Cell Death Differ 11: 1038–1045. 12. Ponzielli R, Katz S, Barsyte-Lovejoy D, Penn LZ (2005) Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer 41: 2485–2501. 13. Gustafson WC, Weiss WA (2010) Myc proteins as therapeutic targets. Oncogene 29: 1249–1259. 14. Muncan V, Sansom OJ, Tertoolen L, Phesse TJ, Begthel H, et al. (2006) Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c- Myc. Mol Cell Biol 26: 8418–8426. 15. Oskarsson T, Essers MA, Dubois N, Offner S, Dubey C, et al. (2006) Skin epidermis lacking the c-Myc gene is resistant to Ras-driven tumorigenesis but can reacquire sensitivity upon additional loss of the p21Cip1 gene. Genes Dev 20: 2024–2029. 16. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, et al. (2008) Modelling Myc inhibition as a cancer therapy. Nature 455: 679–683. 17. Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, et al. (2011) Endogenous Myc maintains the tumor microenvironment. Genes Dev 25: 907–916. 18. Blackwood EM, Eisenman RN (1991) Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251: 1211–1217. 19. Massari ME, Murre C (2000) Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol 20: 429–440. 20. Beckmann H, Kadesch T (1991) The leucine zipper of TFE3 dictates helix-loop- helix dimerization specificity. Genes Dev 5: 1057–1066. 21. Murre C, McCaw PS, Vaessin H, Caudy M, Jan LY, et al. (1989) Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell 58: 537–544. 22. Sun XH, Copeland NG, Jenkins NA, Baltimore D (1991) Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins. Mol Cell Biol 11: 5603–5611. 23. Gordan JD, Thompson CB, Simon MC (2007) HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12: 108–113. 24. Dang CV, Kim JW, Gao P, Yustein J (2008) The interplay between MYC and HIF in cancer. Nat Rev Cancer 8: 51–56. 25. Qing G, Skuli N, Mayes PA, Pawel B, Martinez D, et al. (2010) Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. Cancer Res 70: 10351–10361. 26. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, et al. (2001) Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 3: 392–399. 27. Wu S, Cetinkaya C, Munoz-Alonso MJ, von der Lehr N, Bahram F, et al. (2003) Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 22: 351–360. 28. Herold S, Wanzel M, Beuger V, Frohme C, Beul D, et al. (2002) Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell 10: 509–521. 29. Patel JH, McMahon SB (2006) Targeting of Miz-1 is essential for Myc-mediated apoptosis. J Biol Chem 281: 3283–3289. 30. Peukert K, Staller P, Schneider A, Carmichael G, Hanel F, et al. (1997) An alternative pathway for gene regulation by Myc. EMBO J 16: 5672–5686. The Action Mechanism of Omomyc Contributed reagents/materials/analysis tools: MDC. Wrote the paper: SN. Provided critical discussions and advice: GIE. 31. Kelly K, Cochran BH, Stiles CD, Leder P (1983) Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 35: 603–610. 32. Persson H, Hennighausen L, Taub R, DeGrado W, Leder P (1984) Antibodies to human c-myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. Science 225: 687–693. 33. Eilers M, Schirm S, Bishop JM (1991) The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J 10: 133–141. 34. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, et al. (2004) Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2: E7. 35. Zeller KI, Jegga AG, Aronow BJ, O’Donnell KA, Dang CV (2003) An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 4: R69. 36. Kidder BL, Yang J, Palmer S (2008) Stat3 and c-Myc genome-wide promoter occupancy in embryonic stem cells. PLoS One 3: e3932. 37. Kim J, Chu J, Shen X, Wang J, Orkin SH (2008) An extended transcriptional network for pluripotency of embryonic stem cells. Cell 132: 1049–1061. 38. Lin CH, Lin C, Tanaka H, Fero ML, Eisenman RN (2009) Gene regulation and epigenetic remodeling in murine embryonic stem cells by c-Myc. PLoS One 4: e7839. 39. Chen Y, Blackwell TW, Chen J, Gao J, Lee AW, et al. (2007) Integration of genome and chromatin structure with gene expression profiles to predict c-MYC recognition site binding and function. PLoS Comput Biol 3: e63. 40. Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19: 1–11. 41. Iritani BM, Eisenman RN (1999) c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci U S A 96: 13180–13185. 42. Chandriani S, Frengen E, Cowling VH, Pendergrass SA, Perou CM, et al. (2009) A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS One 4: e6693. 43. Rothermund K, Rogulski K, Fernandes E, Whiting A, Sedivy J, et al. (2005) C- Myc-independent restoration of multiple phenotypes by two C-Myc target genes with overlapping functions. Cancer Res 65: 2097–2107. 44. Dugan KA, Wood MA, Cole MD (2002) TIP49, but not TRRAP, modulates c- Myc and E2F1 dependent apoptosis. Oncogene 21: 5835–5843. 45. O’Connell BC, Cheung AF, Simkevich CP, Tam W, Ren X, et al. (2003) A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 278: 12563–12573. 46. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, et al. (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11: 407–420. 47. Lofstedt T, Fredlund E, Noguera R, Navarro S, Holmquist-Mengelbier L, et al. (2009) HIF-1alpha induces MXI1 by alternate promoter usage in human neuroblastoma cells. Exp Cell Res 315: 1924–1936. 48. Prochownik EV, Eagle Grove L, Deubler D, Zhu XL, Stephenson RA, et al. (1998) Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. Genes Chromosomes Cancer 22: 295–304. 49. Wechsler DS, Shelly CA, Petroff CA, Dang CV (1997) MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res 57: 4905–4912. 50. Bush A, Mateyak M, Dugan K, Obaya A, Adachi S, et al. (1998) c-myc cells misregulate cad and gadd45 but not other proposed c-Myc targets. Genes Dev 12: 3797–3802. 51. Greasley PJ, Bonnard C, Amati B (2000) Myc induces the nucleolin and BN51 genes: possible implications in ribosome biogenesis. Nucleic Acids Res 28: 446–453. 52. Seoane J, Le HV, Massague J (2002) Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419: 729–734. 53. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825. 54. Knoepfler PS, Zhang XY, Cheng PF, Gafken PR, McMahon SB, et al. (2006) Myc influences global chromatin structure. EMBO J 25: 2723–2734. 55. Cotterman R, Jin VX, Krig SR, Lemen JM, Wey A, et al. (2008) N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res 68: 9654–9662. 56. Ogawa H, Ishiguro K, Gaubatz S, Livingston DM, Nakatani Y (2002) A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science 296: 1132–1136. 57. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, et al. (2008) Distinct thresholds govern Myc’s biological output in vivo. Cancer Cell 14: 447–457. 58. Zhong Q, Simonis N, Li QR, Charloteaux B, Heuze F, et al. (2009) Edgetic perturbation models of human inherited disorders. Mol Syst Biol 5: 321. PLoS ONE | www.plosone.org 15 July 2011 | Volume 6 | Issue 7 | e22284